Showing results (251-260 of 296) with videos related to

Sort By:
Pageof 30
European Journal of Nuclear Medicine and Molecular Imaging|September 6, 2021
The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)Matteo Bauckneht, Sara Elena Rebuzzi, Alessio Signori, et al.
Annals of Medicine|April 13, 2023
External validation of unsupervised COVID-19 clinical phenotypes and their prognostic impactDaniele Roberto Giacobbe, Emilio Di Maria, Alberto Stefano Tagliafico, et al.
Cancers|May 16, 2023
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 StudySara Elena Rebuzzi, Matteo Brunelli, Francesca Galuppini, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2024
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [<sup>18</sup>F]PSMA-1007 PET/CTMatteo Bauckneht, Francesca D'Amico, Domenico Albano, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2019
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Marinella Clerico, Stefania Federica De Mercanti, Alessio Signori, et al.
Infectious Diseases and Therapy|July 30, 2021
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)Matteo Bassetti, Daniele Roberto Giacobbe, Paolo Bruzzi, et al.
Journal of the Neurological Sciences|March 26, 2021
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian studyStefania Federica De Mercanti, Alessio Signori, Cinzia Cordioli, et al.
Future Oncology (London, England)|June 11, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
Future Oncology (London, England)|April 29, 2024
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)Fabio Catalano, Matteo Brunelli, Alessio Signori, et al.
European Journal of Neurology|March 29, 2024
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)Irene Schiavetti, Alessio Signori, Angela Albanese, et al.
Pageof 30